Flagship Pioneering combined Torque Therapeutics and Cogen Immune Medicines, which have raised more than $220m, into Repertoire Immune Medicines with an autologous T-cell therapy being studied in a Phase I trial.
The start-up-creating investment firm Flagship Pioneering has combined two companies in its portfolio with complementary technologies into one entity called Repertoire Immune Medicines, which launched on 12 March to decode human immune system synapses and use those insights to develop treatments for cancer, autoimmune diseases and infectious diseases.
The two predecessor companies – Torque Therapeutics Inc. and Cogen Immune Medicines – raised more than $220m prior to their combination
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
